Journal of Shandong University (Health Sciences) ›› 2019, Vol. 57 ›› Issue (4): 113-118.doi: 10.6040/j.issn.1671-7554.0.2018.1401

Previous Articles     Next Articles

Analysis of the proportion of drug expenses and medical insurance payment based on hospitalization expenses of five cancer patients

YANG Yuxia1,2, ZANG Sujie2, LENG Anli1, WANG Jian1   

  1. 1. Department of Social Medicine and Maternal &
    Child Health, School of Public Health, Shandong University, Jinan 250012, Shandong, China;
    2. Medical Insurance Office, The Second Hospital of Shandong University, Jinan 250033, Shandong, China
  • Published:2022-09-27

PDF (PC)

180

Abstract: Objective To analyze the features and variation trends of the hospitalization expenses, drug proportions and payment methods of medical insurances among cancer inpatients between 2013 and 2017, in order to provide references for eliminating drug additions, adjusting medical service prices, and accelerating the establishment of new compensation mechanisms for public hospitals. Methods Patients whose first diagnosis was gastric cancer, lung cancer, colorectal cancer, esophageal cancer, or breast cancer were selected from a tertiary hospital in Shandong Province from 2013 to 2017. The characteristics of hospitalization expenses were described. The trends in different years were analyzed with one-way ANOVA and χ2 test. Results A total of 20 138 inpatients were involved. In 2017, patients with esophageal cancer had the highest hospitalization expenses(34 137.96 yuan). From 2013 to 2017, the drug proportions were generally on the decline, but there was no obvious decrease in hospitalization expenses. On the contrary, the hospitalization expenses of lung cancer patients increased significantly. In addition, there was a large gap in the compensation proportions among the three types of medical insurances. Conclusion The annual decrease of drug proportion does not bring significant reduction to hospitalization expenses. The economic burden of cancer inpatients is still heavy. The drug proportion should continue to be reduced based on the controlling of the total hospitalization expenses. The gap in the compensation proportion of various types of medical insurances should be narrowed to effectively alleviate the financial burden of patients.

Key words: Cancer, Hospitalization expenses, Drug proportion, Overall payment of medical insurance

CLC Number: 

  • R73
[1] Laudicella M, Walsh B, Burns E, et al. Cost of care for cancer patients in England: evidence from population-based patient-level data[J]. Br J Cancer, 2016, 114(11): 1286-1292.
[2] Mariotto AB, Yabroff KR, Shao YW, et al. Projections of the cost of cancer care in the United States: 2010-2020[J]. J Natl Cancer Inst, 2011, 103(2): 117-128.
[3] Luengo-Fernandez R, Leal J, Gray A, et al. Economic burden of cancer across the European Union: a population-based cost analysis[J]. Lancet Oncol, 2013, 14(12): 1165-1174.
[4] Wei F, Wu YF, Tang L, et al. Trend analysis of cancer incidence and mortality in China[J]. Sci China Life Sci, 2017, 60(11): 1271-1275.
[5] 段纪俊, 严亚琼, 杨念念, 等. 中国恶性肿瘤发病与死亡的国际比较分析[J/CD]. 中国医学前沿杂志(电子版), 2016, 8(7): 17-23. DUAN Jijun, YAN Yaqiong, YANG Niannian, et al. International comparison analysis of Chinas cancer incidence and mortality[J/CD]. Chinese Journal of the Frontiers of Medical Science(Electronic Version), 2016, 8(7): 17-23.
[6] 段纪俊, 陈万青, 张思维, 等. 中国恶性肿瘤死亡率的国际比较[J]. 中国社会医学杂志, 2009, 26(6): 377-378. DUAN Jijun, CHEN Wanqing, ZHANG Siwei, et al. International comparison of maligant tumor mortality[J]. Chinese Journal of Social Medicine, 2009, 26(6): 377-378.
[7] 郑荣寿, 顾秀瑛, 李雪婷, 等. 2000~2014年中国肿瘤登记地区癌症发病趋势及年龄变化分析[J]. 中华预防医学杂志, 2018, 52(6): 593-600. ZHENG Rongshou, GU Xiuying, LI Xueting, et al. Analysis on the trend of cancer incidence and age change in cancer registry areas of China, 2000 to 2014[J]. Chinese Journal of Preventive Medicine, 2018, 52(6): 593-600.
[8] Chen WQ, Zheng RS, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[9] 付振涛, 徐爱强, 赵滢, 等. 2013年山东省恶性肿瘤发病和死亡水平分析[J]. 中华肿瘤防治杂志, 2017, 24(18): 1261-1267. FU Zhentao, XU Aiqiang, ZHAO Ying, et al. Cancer incidence and mortality in Shandong province, 2013[J]. Chinese Journal of Cancer Prevention and Treatment, 2017, 24(18): 1261-1267.
[10] Kim S, Kwon S. Impact of the policy of expanding benefit coverage for cancer patients on catastrophic health expenditure across different income groups in South Korea[J]. Soc Sci Med, 2015, 138: 241-247. doi:10.1016/j.socscimed.2015.06.012.
[11] 马莉, 陈学忠, 刘元强, 等. 兰州市四种常见老年癌症直接经济负担分析[J]. 中国老年学杂志, 2011, 31(17): 3352-3354.
[12] 张义华, 王增珍. 恶性肿瘤患者年住院费用研究[J]. 中国卫生经济, 2006, 25(12): 72-73.
[13] 董惠玲, 鹿子龙, 王媛媛, 等. 2010-2012年山东省6县区主要恶性肿瘤疾病负担研究[J]. 现代预防医学, 2016, 43(7): 1235-1238. DONG Huiling, LU Zilong, WANG Yuanyuan, et al. Burden of malignant tumor in six counties of Shandong, 2010-2012[J]. Modern Preventive Medicine, 2016, 43(7): 1235-1238.
[14] Chien CR, Shih YC. Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer(NSCLC)[J]. Clinicoecon Outcomes Res, 2012, 4: 201-208. doi:10.2147/CEOR.S27770.
[15] Elkin EB, Bach PB. Cancers next frontier: addressing high and increasing costs[J]. JAMA, 2010, 303(11): 1086-1087.
[16] 马金姝, 王莹. 济南市2009-2012年居民人口及疾病负担分析[J]. 中国公共卫生, 2014, 30(2): 222-224. MA Jinshu, WANG Ying. Population burden and burden of disease in Ji'nan city, 2009-2012[J]. Chinese Journal of Public Health, 2014, 30(2): 222-224.
[17] Xu K, Evans DB, Kawabata K, et al. Household catastrophic health expenditure: a multicountry analysis[J]. Lancet, 2003, 362(9378): 111-117.
[18] 王梅, 王媛媛, 郭斌, 等. 我国肺癌疾病的直接住院费用负担现状及其问题[J]. 中国卫生经济, 2007, 26(6): 59-62. WANG Mei, WANG Yuanyuan, GUO Bin, et al. Status quo and issues of direct impatient cost of lung carcinoma in China[J]. Chinese Health Economics, 2007, 26(6): 59-62.
[19] 石春雷, 娄培安, 石菊芳, 等. 中国1996-2014年肺癌经济负担研究系统评价[J]. 中国公共卫生, 2017, 33(12): 1767-1774. SHI Chunlei, LOU Pei'an, SHI Jufang, et al. Economic burden of lung cancer in mainland China, 1996-2014: a systematic review[J]. Chinese Journal of Public Health, 2017, 33(12): 1767-1774.
[20] 王增亮, 张国丽, 冯德坤, 等. 基于病案首页数据的肺恶性肿瘤患者住院费用分析[J]. 中国病案, 2018, 19(3): 74-77. WANG Zengliang, ZHANG Guoli, FENG Dekun, et al. Analysis on the hospitalization expenditure of lung cancer based on front pages of medical records[J]. Chinese Medical Record, 2018, 19(3): 74-77.
[21] 赵少峰, 吕红亮, 彭映姝, 等. 肺癌患者住院费用影响因素分析: 以四川省某三甲医院为例[J]. 预防医学情报杂志, 2014, 30(5): 342-345. ZHAO Shaofeng, LÜ Hongliang, PENG Yingshu, et al. Study on factors influencing hospitalization expenses of lung cancer in a tertiary hospital of Sichuan[J]. Journal of Preventive Medicine Information, 2014, 30(5): 342-345.
[22] 陈治水, 冷家骅, 高广颖, 等. 五类肿瘤疾病住院费用及其影响因素分析[J]. 中国卫生经济, 2014, 33(7): 57-60. CHEN Zhishui, LENG Jiahua, GAO Guangying, et al. Analysis on hospitalization expense of five kinds of cancers and its influencing factors[J]. Chinese Health Economics, 2014, 33(7): 57-60.
[23] 浙江将15种大病“高价药”纳入医保[J]. 中国医疗保险, 2015, 3: 72.
[24] Yip WC, Hsiao WC, Chen W, et al. Early appraisal of China's huge and complex health-care reforms[J]. Lancet, 2012, 379(9818): 833-842.
[25] 王翠娟, 尚明, 佟峰. 山东省肺癌住院患者直接经济负担影响因素分析[J]. 中国医院统计, 2016, 4: 254-257. doi: 10.3969/j.issn.1006-5253.2016.04.005. WANG Cuijuan, SHANG Ming, TONG Feng. Study on the influencing factors of direct economic burden and medical insurance system of lung cancer patients in Shandong Province[J]. Chinese Journal of Hospital Statistics, 2016, 4: 254-257. doi: 10.3969/j.issn.1006-5253.2016.04.005.
[1] LIN Mingxia, LIU Guibin, MA Yanhua, LIAN Zhaoyu, REN Yangyang. ATPase copper transporting alpha mediated cuproptosis pathway and its value in cancer therapy [J]. Journal of Shandong University (Health Sciences), 2026, 64(4): 117-124.
[2] HUANG Peiwen, WANG Xudong. A new drug for non-small cell lung cancer: Telisotuzumab Vedotin, an antibody-drug conjugate targeting c-Met protein [J]. Journal of Shandong University (Health Sciences), 2026, 64(3): 124-130.
[3] GU Chunqing, GUO Ruisi, ZHOU Qinqin, LIU Henghui, BA Wanyu, SUN Shiling, WANG Bing, ZHENG Yuling, WU Suhui. Mechanism of Suanzaoren-Yuanzhi drug pair in the treatment of breast cancer related insomnia based on network pharmacology and animal experiments [J]. Journal of Shandong University (Health Sciences), 2026, 64(1): 99-108.
[4] LI Jing, JU Weihang, LIU Ke. Pan-cancer cell type-specific gene-gene co-expression pattern [J]. Journal of Shandong University (Health Sciences), 2025, 63(9): 31-39.
[5] LI Xuekai, SUN Linhan, LIU Duanrui, NI Yang. Research progress on the function and mechanism of lactylation in the process of tumor inflammation and cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(9): 65-76.
[6] LI Ziqi, WEI Yanruoxue, LIU Xiaohan, LIU Chuncheng, ZHAO Ran, LIU Yukun. The functional role and clinical significance of lncRNA HEATR3-AS1 in colorectal cancer tumorigenesis and progression [J]. Journal of Shandong University (Health Sciences), 2025, 63(9): 108-115.
[7] ZHANG Runze, XUE Fuzhong, YANG Fan. Cancer subtype clustering via multimodal decoupled contrastive learning [J]. Journal of Shandong University (Health Sciences), 2025, 63(8): 51-60.
[8] LI Qian, YANG Fan, XUE Fuzhong. Multi-cancer risk prediction model based on multi-modal data fusion [J]. Journal of Shandong University (Health Sciences), 2025, 63(8): 79-85.
[9] LIU Baoguo, SONG Xiang, ZHAO Xiaowen, MAO Yali. Application value of serum STAT5B and NKAIN1 mRNA detection in breast cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(7): 68-74.
[10] WANG Lei, CHANG Xiao, WANG Zimeng, LI Jiaojiao, CUI Shujun, YANG Fei, ZHU Yuexiang. Predictive value of intratumoral and peritumoral DCE-MRI imaging histology for progression-free survival in patients with cervical cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(6): 45-54.
[11] WANG Xuemei, YANG Hao, SONG Yang, CHENG Shichao, ZHANG Tingting, WANG Yanchun. Causal association of antidiabetic drugs with female malignant tumours: a two-sample Mendelian randomisation study [J]. Journal of Shandong University (Health Sciences), 2025, 63(6): 67-77.
[12] ZHU Yongcai, XIE Yan, QI Qiuchen, LI Peilong, WANG Chuanxin, DU Lutao. Value of a combined model based on ATM gene methylation of peripheral blood mononuclear cells in the early diagnosis of pancreatic cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(6): 78-88.
[13] ZHAO Hanqing, ZHOU Xinrui, LI Zijian, TANG Xing. Application of circulating tumor cells combined with serological detection in non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(5): 79-85.
[14] DU Xue, LI Chunxia, LIU Yunxia, ZHANG Tao. Dynamic prediction model for the colorectal cancer patients prognosis based on MFPC-Cox [J]. Journal of Shandong University (Health Sciences), 2025, 63(5): 101-110.
[15] ZHANG Yongyuan, WANG Qingliang, LIAN Xuehong. Structural changes and influencing factors of hospitalization expenses for rare diseases patients in a tertiary general hospital in Shandong Province [J]. Journal of Shandong University (Health Sciences), 2025, 63(5): 111-119.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd